Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04397159
Other study ID # F3423-W
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2022
Est. completion date April 1, 2026

Study information

Verified date May 2024
Source VA Office of Research and Development
Contact Jared M Gollie, PhD
Phone (202) 745-8000
Email Jared.Gollie@va.gov
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The VA health care system uses a health promotion-focused model which aims to provide longitudinal care through a patient-aligned care team for Veterans with chronic kidney disease. Since the largest subpopulation of Veterans with chronic kidney disease is comprised of those not requiring dialysis, neuromuscular screening assessments may provide valuable information regarding an individual overall health status and potential for future complications. Furthermore, identifying at risk individuals early in the disease process will allow for the prescription of timely interventions. Exercise strategies such as combination exercise, which uses flywheel resistance plus aerobic exercise, may provide a valuable treatment option for combating neuromuscular dysfunction and functional decline in patients with chronic kidney disease.


Description:

Chronic kidney disease (CKD) is a complex medical condition affecting as much as 36% of the Veteran population. Both empirical and anecdotal evidence identify elevations in fatigability as a major health concern in Veterans with CKD predialysis. Neuromuscular deteriorations resulting from CKD are likely to contribute to excessive fatigability, impacting an individual's functional status. Flywheel resistance exercise (FRE) uses inertial resistance to allow for optimal muscle loading through the entire concentric muscle action and promotes greater eccentric force generation compared to traditional resistance exercise. FRE has been shown to be superior to traditional resistance exercise for improving muscle strength, power, and physical function in healthy populations suggesting it may be a useful treatment for addressing neuromuscular impairments and functional decline. However, it is unclear if the addition of aerobic exercise to FRE would provide additive improvements in fatigue resistance in patients with CKD, without compromising neuromuscular and functional benefits. The purpose of this project is to (1) advance the understanding of performance fatigability and perceived fatigability, and the association with neuromuscular capacity in Veterans with CKD stage 3 & 4 predialysis and (2) determine the extent to which combination FRE plus aerobic exercise training can improve fatigability status, neuromuscular capacity, and physical function in Veterans with CKD stage 3 & 4 predialysis. The central hypothesis is that reductions in neuromuscular capacity are associated with increases in fatigability severity, and that FRE plus aerobic exercise training will reduce fatigability severity while enhancing neuromuscular and functional capabilities in Veterans with CKD stage 3 & 4 predialysis. To address this hypothesis, researchers will characterize performance fatigability and perceived fatigability, and assess the associations between fatigability outcomes and neuromuscular capacity in Veterans with CKD stage 3 & 4 predialysis and examine the effects of 12-weeks of FRE plus aerobic exercise training on changes in performance and perceived fatigability, neuromuscular capacity, and physical function in Veterans with CKD stage 3 & 4 predialysis. Findings from this project will provide valuable information for advancing the understanding of performance fatigability and perceived fatigability, and their inter-relationship, in Veterans with CKD stages 3 and 4. Additionally, novel evidence on the responsiveness of performance and perceived fatigability, neuromuscular capacity, and quality of life to FRE plus aerobic exercise training will be gained.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date April 1, 2026
Est. primary completion date April 1, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 85 Years
Eligibility Inclusion Criteria: - Ambulatory (with or without a gait aid), 50 years of age or older diagnosed with chronic kidney disease (CKD) stages 3 & 4 predialysis (as defined by eGFR 59-15 ml/min per 1.73m2) - Control group will include ambulatory individuals without clinical evidence of kidney disease (defined by eGRF >60 ml/min per 1.73m2) within the last 12-months - All participants must be able to speak and read English, and demonstrate orientation to person, place, and time Exclusion Criteria: - adults diagnosed with acute renal failure/injury within the last 12-months - non-ambulatory individuals - adults who do not use the DC VAMC as their main site for renal care - those who have any uncontrolled cardiovascular - musculoskeletal disease - or other conditions that, in the opinion of the principal investigator, could make participation in the study unsafe - any orthopedic or joint pain which would prevent the participant from safely engaging in the study protocol - additionally, individuals with plans to relocate from the DC metro area within one year will not be eligible for the intervention portion of the study

Study Design


Intervention

Behavioral:
Combination Exercise
Flywheel Resistance Plus Aerobic Exercise

Locations

Country Name City State
United States Washington DC VA Medical Center, Washington, DC Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other change in muscle activation Muscle activation of the vastus lateralis will be determined using electromyography as the root mean square during isometric knee extensions. week 12
Other change in interleukin 6 (IL-6) and tumor necrosis factor alpha Interleukin 6 (IL-6) (pg/ml) and tumor necrosis factor alpha (pg/ml) will be assessed from blood samples. week 12
Other change in health-related quality of life Health-related quality of life will be assessed using the Short-form 36 week 12
Other change in high density c-reactive protein Change in high density c-reactive protein (mg/L) will be assessed from blood samples. week 12
Primary change in knee extensor fatigability Knee extensor fatigability will be assessed as changes in torque of the dominant leg during 30 contractions. week 6 and 12
Primary change in perceived fatigability Rating of perceived fatigability will be assessed using a 10-point scale with 0 indicating "not fatigued at all" and 10 indicating "absolutely exhausted". Low scores reflect lower perceived fatigability. week 6 and 12
Primary change in muscle blood flow Muscle blood flow of the vastus lateralis will be assessed using near-infrared spectroscopy and determined as the change in total hemoglobin during venous occlusion test. week 6 and 12
Secondary change in muscle Quality Muscle quality of the vastus lateralis will be assessed using diagnostic ultrasound and determined using grayscale analysis. week 12
Secondary change in Sit-to-Stand Sit-to-stand test will be used to assess physical function and determined as the time taken to complete five sit-to-stand repetitions. week 12
Secondary change in rate of torque development Rate of torque development will be calculated as the change in torque over the change in time during isometric knee extensions. week 12